Neuphoria Therapeutics (NEUP) Proxy filing summary

Executive summary

• All-share merger between two biotech firms to create a combined company focused on immunotherapies, with a Nasdaq listing and continued AIM listing.

• The merger is structured so that existing shareholders of the acquiring company will own 85.5% and the target's shareholders 14.5% of the combined entity, subject to adjustments.

• Financing of up to $89 million is expected through a mix of private placement, UK placing, retail offer, and debt financing, supporting a Phase 3 trial for the lead asset.

• The transaction is unanimously approved by both boards and is subject to shareholder and regulatory approvals.

• The combined company will focus on advancing a pipeline of targeted immunotherapies, with the lead program in advanced melanoma.

Voting matters and shareholder proposals

• Completion of the merger requires approval by shareholders of both companies.

• Voting and support agreements have been secured from key directors and shareholders of both companies.

• Lock-up agreements will restrict transfers of shares by directors and certain shareholders for 180 days post-completion.

• If shareholder approval is not obtained, the party failing to secure approval must reimburse the other’s transaction expenses.

Board of directors and corporate governance

• The combined board will include a new non-executive director from the acquired company, subject to due diligence.

• The board composition and governance structure are designed to meet Nasdaq independence requirements.